271 related articles for article (PubMed ID: 27984656)
21. Five-year outcomes of squamous cell carcinoma of the tonsil treated with radiotherapy.
Mourad WF; Hu KS; Puckett L; Hauerstock D; Shourbaji RA; Li Z; Manolidis S; Schantz S; Tran T; Jacobson A; Urken M; Culliney B; Persky M; Harrison LB
Am J Clin Oncol; 2014 Feb; 37(1):57-62. PubMed ID: 23357967
[TBL] [Abstract][Full Text] [Related]
22. Chemoradiotherapy followed by consolidation chemotherapy involving paclitaxel and carboplatin and in FIGO stage IIIB/IVA cervical cancer patients.
Mabuchi S; Isohashi F; Okazawa M; Kitada F; Maruoka S; Ogawa K; Kimura T
J Gynecol Oncol; 2017 Jan; 28(1):e15. PubMed ID: 27958682
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of combined radiotherapy with EGFR inhibitors and chemotherapy for laryngeal organ preservation in patients with locally advanced hypopharyngeal carcinomas.
Zhang X; Wang J; Wu W; Liu M; Zhao F; Du L; Huang D; Yang S; Ma L
Curr Cancer Drug Targets; 2014; 14(6):589-98. PubMed ID: 25039274
[TBL] [Abstract][Full Text] [Related]
24. Outcomes of intensity-modulated radiotherapy as primary treatment for oropharyngeal squamous cell carcinoma - a European singleinstitution analysis.
Bird T; De Felice F; Michaelidou A; Thavaraj S; Jeannon JP; Lyons A; Oakley R; Simo R; Lei M; Guerrero Urbano T
Clin Otolaryngol; 2017 Feb; 42(1):115-122. PubMed ID: 27185284
[TBL] [Abstract][Full Text] [Related]
25. Hyperfractionated accelerated radiation therapy plus cetuximab plus cisplatin chemotherapy in locally advanced inoperable squamous cell carcinoma of the head and neck : Final 5‑year results of a phase II study.
Kuhnt T; Schreiber A; Pirnasch A; Hautmann MG; Hass P; Sieker FP; Engenhart-Cabillic R; Richter M; Dellas K; Dunst J
Strahlenther Onkol; 2017 Sep; 193(9):733-741. PubMed ID: 28500491
[TBL] [Abstract][Full Text] [Related]
26. Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis.
Xiang M; Holsinger FC; Colevas AD; Chen MM; Le QT; Beadle BM
Cancer; 2018 Dec; 124(23):4486-4494. PubMed ID: 30332498
[TBL] [Abstract][Full Text] [Related]
27. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
[TBL] [Abstract][Full Text] [Related]
28. Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.
Zumsteg ZS; Kim S; David JM; Yoshida EJ; Tighiouart M; Shiao SL; Scher K; Mita A; Sherman EJ; Lee NY; Ho AS
Cancer; 2017 May; 123(9):1555-1565. PubMed ID: 28001302
[TBL] [Abstract][Full Text] [Related]
29. It is not just IMRT: Human papillomavirus related oropharynx squamous cell carcinoma is associated with better swallowing outcomes after definitive chemoradiotherapy.
Naik M; Ward MC; Bledsoe TJ; Kumar AM; Rybicki LA; Saxton JP; Burkey BB; Greskovich JF; Adelstein DJ; Koyfman SA
Oral Oncol; 2015 Aug; 51(8):800-4. PubMed ID: 25977228
[TBL] [Abstract][Full Text] [Related]
30. Re-irradiation with cetuximab or cisplatin-based chemotherapy for recurrent squamous cell carcinoma of the head and neck.
Dornoff N; Weiß C; Rödel F; Wagenblast J; Ghanaati S; Atefeh N; Rödel C; Balermpas P
Strahlenther Onkol; 2015 Aug; 191(8):656-64. PubMed ID: 26004121
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of cetuximab in combination with 5-fluorouracil, mitomycin C and radiotherapy in patients with locally advanced anal cancer.
Leon O; Guren MG; Radu C; Gunnlaugsson A; Johnsson A
Eur J Cancer; 2015 Dec; 51(18):2740-6. PubMed ID: 26597443
[TBL] [Abstract][Full Text] [Related]
32. Effect of human papillomavirus on patterns of distant metastatic failure in oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
Trosman SJ; Koyfman SA; Ward MC; Al-Khudari S; Nwizu T; Greskovich JF; Lamarre ED; Scharpf J; Khan MJ; Lorenz RR; Adelstein DJ; Burkey BB
JAMA Otolaryngol Head Neck Surg; 2015 May; 141(5):457-62. PubMed ID: 25742025
[TBL] [Abstract][Full Text] [Related]
33. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
[TBL] [Abstract][Full Text] [Related]
34. OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Seiwert TY; Foster CC; Blair EA; Karrison TG; Agrawal N; Melotek JM; Portugal L; Brisson RJ; Dekker A; Kochanny S; Gooi Z; Lingen MW; Villaflor VM; Ginat DT; Haraf DJ; Vokes EE
Ann Oncol; 2019 Feb; 30(2):297-302. PubMed ID: 30481287
[TBL] [Abstract][Full Text] [Related]
35. Treatment: Outcome and Toxicity of Volumetric Modulated Arc Therapy in Oropharyngeal Carcinoma.
Franzese C; Fogliata A; Franceschini D; Clerici E; D'Agostino G; Navarria P; Mancosu P; Tomatis S; Cozzi L; Scorsetti M
Anticancer Res; 2016 Jul; 36(7):3451-7. PubMed ID: 27354607
[TBL] [Abstract][Full Text] [Related]
36. Outcomes and toxicities for the treatment of stage IVB cervical cancer.
Hwang JH; Lim MC; Seo SS; Kang S; Park SY; Kim JY
Arch Gynecol Obstet; 2012 Jun; 285(6):1685-93. PubMed ID: 22173823
[TBL] [Abstract][Full Text] [Related]
37. Concurrent cisplatin or cetuximab with radiotherapy for HPV-positive oropharyngeal cancer: Medical resource use, costs, and quality-adjusted survival from the De-ESCALaTE HPV trial.
Jones DA; Mistry P; Dalby M; Fulton-Lieuw T; Kong AH; Dunn J; Mehanna HM; Gray AM
Eur J Cancer; 2020 Jan; 124():178-185. PubMed ID: 31794928
[TBL] [Abstract][Full Text] [Related]
38. Prediction of acute toxicity grade ≥ 3 in patients with locally advanced non-small-cell lung cancer receiving intensity modulated radiotherapy and concurrent low-dose Cisplatin.
Uyterlinde W; Belderbos J; Baas C; van Werkhoven E; Knegjens J; Baas P; Smit A; Rikers C; van den Heuvel M
Clin Lung Cancer; 2013 Sep; 14(5):541-8. PubMed ID: 23835165
[TBL] [Abstract][Full Text] [Related]
39. Artificial nutrition dependence after cetuximab versus cisplatin combined with radiotherapy for advanced head and neck cancer: A propensity score-matched analysis.
Ishimaru M; Ono S; Suzuki S; Matsui H; Fushimi K; Yasunaga H
Head Neck; 2017 Feb; 39(2):320-325. PubMed ID: 27635865
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and toxicity of concurrent chemoradiotherapy in patients with advanced oropharyngeal squamous cell carcinoma.
Mori M; Tsukuda M; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Komatsu M; Niho T; Sakuma N; Miyakoshi A; Isono Y; Iwahana S
Cancer Chemother Pharmacol; 2011 Oct; 68(4):855-62. PubMed ID: 21229356
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
